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Summary
In the coding part and the intron-exon boundaries of
the androgen-receptor gene of a patient with partial
androgen insensitivity, no mutation was found. The
androgen receptor of this patient displayed normal
ligand-binding parameters and migrated as a 110–112-
kD doublet on SDS-PAGE in the absence of hormone.
However, after culturing of the patient’s genital skin
fibroblasts in the presence of hormone, the slower-
migrating 114-kD protein, which reflects hormone-
dependent phosphorylation, was hardly detectable.
Furthermore, receptor protein was undetectable in the
nuclear fraction of the fibroblasts, after treatment with
hormone, which is indicative of defective DNA binding.
By sequencing part of intron 2, a TrA mutation was
found 11 bp upstream of exon 3. In our screening of
102 chromosomes from unrelated individuals, this base-
pair substitution was not found, indicating that it was
not a polymorphism. mRNA analysis revealed that
splicing involved a cryptic splice site, located 71/70 bp
upstream of exon 3, resulting in generation of mRNA
with an insert of 69 nucleotides. In addition, a small
amount of a transcript with a deleted exon 3 and a very
low level of wild-type transcript were detected.
Translation of the extended transcript resulted in an
androgen-receptor protein with 23 amino acid residues
inserted between the two zinc clusters, displaying
defective DNA binding and defective transcription
activation.
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Introduction
Expression of a number of genes involved in male sex
differentiation and development is regulated by the an-
drogen receptor (AR). The AR belongs to the family of
steroid hormone–activated transcription modulators
(Evans 1988). Like the other steroid hormone receptors,
the AR consists of distinct functional domains. The N-
terminal part is involved in transcription activation and
is encoded by exon 1 (Faber et al. 1989). Two highly
conserved DNA-binding zinc clusters are encoded by
exons 2 and 3. The N-terminal zinc cluster recognizes
specific consensus DNA sequences, whereas the C-ter-
minal zinc cluster is involved in dimerization (Dahlman-
Wright et al. 1991; Luisi et al. 1991). Parts of exons 3
and 4 encode the hinge region, which contains a nuclear-
localization signal that is involved in nuclear import, and
exons 4–8 encode the ligand-binding domain (LBD).
On ligand binding, the AR undergoes conformational
changes and binds to androgen-response elements
(AREs) in the promoter regions of androgen-regulated
target genes (Beato and Sa´nchez-Pacheco 1996). Re-
cently, coactivators interacting with the LBD of steroid
hormone receptors have been cloned (reviewed by Hor-
witz et al. 1996). One of these, ARA70, appears to be
specifically involved in transcription activation by the
AR (Yeh and Chang 1996).
Defects in the human AR (hAR) cause disturbed vi-
rilization in 46,XY individuals, which is called the “an-
drogen insensitivity syndrome” (AIS) (reviewed by Quig-
ley et al. 1995). Many qualitative and quantitative AR
abnormalities, causing a broad range of AIS phenotypes,
have been described (Gottlieb et al. 1997). The spectrum
of phenotypes ranges from individuals with completely
female external genitalia and absence of Mu¨llerian- and
Wolffian-duct derivatives (complete AIS) to patients with
ambiguous genitalia (partial AIS) or with mild hypospa-
dias (Quigley et al. 1995). The mutations that are most
frequently observed are nonsense or missense point mu-
tations. Mutations resulting in aberrant splicing are
much less common; only six of them have been reported
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Figure 1 Pedigree and sizing of the polyglutamine stretch of the
family with AIS. PCR products, obtained by amplification of genomic
DNA by primers flanking the (CAG)nCAA repeat, were resolved on a
7% denaturating polyacrylamide gel. Lane 1, Normal male. Lane 2,
Mother of index subject. Lane 3, 46,XY sister of index subject. Lane
4, 46,XY index subject. Lane 5, Normal male. Lane 6, 46,XY affected
aunt. The index subject (III-2) is indicated by the arrow. Numbers to
the left of the gel represent the number of glutamine residues encoded
by the (CAG)nCAA repeat.
(Gottlieb et al. 1997). In five of these, a consensus splice-
donor site was mutated, resulting in complete AIS.
PCR-SSCP analysis is a screening method often used
for mutation detection in the hAR. Using this method,
we and others have reported that in some individuals,
clinically diagnosed as having AIS, no mutation was
found in the coding region and exon-flanking intronic
sequences of the AR gene (Morel et al. 1994; Bru¨ggen-
wirth et al. 1996; Weidemann et al. 1996). In the present
study, we investigated and characterized the AR gene of
a patient with partial AIS. Initially, no mutation was
detected in the coding region of the AR gene in this
patient, although several biochemical and cell biological
assays revealed that the encoded AR of this patient was
unable to bind to DNA.
Subjects and Methods
Clinical Subjects
A family with three individuals clinically suspect for
AIS (II-4, III-1, and III-2; for pedigree, see fig. 1) was
referred for further diagnosis, treatment, and genetic
counseling. All affected individuals were 46,XY and had
a female habitus with normal female external genitalia,
and normal but underdeveloped testes with epididymi-
des and vasa deferentia were present. No Mu¨llerian rem-
nants were found. One postpubertal patient (II-4) was
Tanner P3,M5 and had axillary hair. Testosterone-syn-
thesis disorders, which could be another cause for such
a 46,XY phenotype, were excluded by analysis of the
circulating levels of steroid hormones and their precur-
sors in this patient. At the age of 15.5 years, she had a
normal male level of testosterone (21 nmol/liter) (normal
range in adults 10–30 nmol/liter) combined with high
levels of LH (13 IU/liter) (normal range in adult males
1.5–8 IU/liter). For final proof of the diagnosis and for
the purpose of genetic counseling of this family, DNA
analysis of the AR gene was started. Blood cells were
obtained from the three 46,XY patients, and genital skin
fibroblasts (GSF) were obtained from III-1 and III-2. GSF
containing wild-type AR protein and AR protein with
an exon 3 deletion, derived from a patient with Reifen-
stein syndrome, previously described by Ris-Stalpers et
al. (1994), were used for comparison. Genomic DNA
from 74 unrelated individuals was used for intron 2
screening. Informed consent was obtained from all
individuals.
Mutation Detection
Genomic DNA was isolated from blood cells or GSF,
according to standard procedures (Sambrook et al.
1989). SSCP analysis and direct sequencing were per-
formed as described elsewhere (Bru¨ggenwirth et al.
1996). A total of 102 normal chromosomes from un-
related individuals were analyzed by automated sequenc-
ing. Template was made by use of intron 2 sense primer
C1 and intron 3 antisense primer C2 (Lubahn et al.
1989) and was purified by use of the Boehringer High
Pure PCR Product Purification Kit (Boehringer Mann-
heim). Sequencing was performed with antisense primer
3BB (table 1). Determination of the length of the poly-
morphic CAG repeat in exon 1, used as an intragenic
polymorphic marker, was performed according to the
method of Sleddens et al. (1992).
Reverse-Transcriptase–PCR (RT-PCR) Reaction
Total RNA was extracted from GSF by use of TRIzol
reagent (Gibco BRL) and was quantified by absorption
at 260 nm. Amplification of genomic DNA was pre-
vented because the primers used in the RT-PCR reaction
resulted in a PCR product spanning several introns of
the AR gene. In the cDNA-synthesis reaction, the exon
5 antisense primer 5BB (table 1) was used for first-strand
cDNA synthesis. cDNA amplification was performed by
PCR with antisense primer 5BB combined with sense
primer J3A (table 1), spanning the 3′ end of exon 1 and
the 5′ end of exon 2. To obtain sufficient quantities of
template DNA spanning the sequences of exons 2 and
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Table 1
Oligonucleotides Used for cDNA Synthesis and Allele-Specific Hybridization
Oligonucleotide Location Sequencea
3BB Intron 3 5′-AGAGAAAGAAAAGTATCTTAC-3′
5BB Exon 5 5′-CGAAGTAGAGgATCCTGGAGTT-3′
J3A Exons 1 and 2 5′-gAtGGatcCATGCGTTTGGAGACTGC-3′
14NB Exon 4 5′-TGCAAAGGAGTtGGGCTGGTTG-3′
470A Exon 1 5′-GTAGCCCCCTACGGCTACA-3′
Wild type Exons 2 and 3 5′-GCTGAAGGGAAACAG-3′
69-bp insertion Exon 2 and intron 2 5′-CTGAAGAAATACCCG-3′
Exon 3 deletion Exons 2–4 5′-CTGAAGCCCGGAAGC-3′
2AA Exon 2 5′-CAGAAGACCTGCCTGATCTGT0-3′
a Lowercase lettering indicates mismatches.
3, for direct sequencing, a nested-PCR reaction was per-
formed by use of sense primer J3A and exon 4 antisense
primer 14NB (table 1).
Ligand-Binding Study
For determination of ligand-binding characteristics of
the AR of the AIS patients, a whole-cell assay was per-
formed on GSF, as described elsewhere (Bru¨ggenwirth
et al. 1996).
Western Blot Analysis
AR protein, obtained from cultured GSF or transiently
transfected Chinese-hamster-ovary (CHO) and COS-1
cells, was immunoprecipitated and analyzed by western
immunoblotting according to the method of Ris-Stalpers
et al. (1991).
Construction of Expression Vectors
Human wild-type AR cDNA expression plasmid
pSVAR0 (Brinkmann et al. 1989) was used to construct
pSVAR129, encoding an AR with 23 additional amino
acid residues between the two zinc clusters. To this end,
the 472-bp KpnI-AspI fragment from pSVAR0 was ex-
changed with the 541-bp KpnI-AspI fragment, generated
by RT-PCR, from the AR mRNA of patient III-2. cDNA
was synthesized as described in the Mutation Detection
subsection above. In the PCR reaction, following first-
strand cDNA synthesis, exon 1 sense primer 470A (table
1) was used, allowing digestion with KpnI. A nested PCR
was performed by use of sense primer 470A and exon
4 antisense primer 14NB (table 1). All PCR products
were checked by sequencing. Expression plasmid BHEX-
AR33, an expression plasmid with an in-frame deletion
of exon 3, was constructed as described elsewhere (Ris-
Stalpers et al. 1994). To generate pSG5AR129 and
pSG5AR33, both the 541-bp KpnI-AspI fragment con-
taining the additional 69 bp and the 355-bp fragment
from which exon 3 had been deleted were exchanged
with the 472-bp KpnI-AspI fragment of wild-type AR
expression vector pSG5AR0 (kindly provided by Dr. A.
C. B. Cato, Karlsruhe, Germany). pSG5 plasmids were
used to obtain AR protein for gel-retardation assays.
Cell Culture and Transfections
GSF and COS-1 cells were cultured as described by
Ris-Stalpers et al. (1990). CHO cells were treated like
COS-1 cells. CHO cells were plated in 7-cm2 wells and
were grown for 24 h before they were transiently trans-
fected, by use of the calcium phosphate method (Chen
and Okayama 1987), with AR expression plasmid (10
ng DNA/ml precipitate suspension) and the mouse mam-
mary tumor virus (MMTV)–Luc reporter plasmid (2 mg
DNA/ml precipitate suspension) (de Ruiter et al. 1995).
Carrier DNA (pTZ19) was added to an end concentra-
tion of 20 mg DNA/ml precipitate suspension, and 90 ml
precipitate suspension was added per well. Twenty-four
hours after transfection, cells were incubated with in-
creasing concentrations of R1881. Luciferase assays
were performed as described above, after 24-h incuba-
tion (Kuil et al. 1995). Each receptor mutant was assayed
three times in triplicate, by use of three independently
isolated expression-plasmid preparations. Luciferase ac-
tivity was related to basal activity, measured in the ab-
sence of hormone. CHO cells, used for expression stud-
ies, were plated in 175-cm2 culture flasks and were
transfected with 200 ml DNA precipitate, as described
above, by use of the calcium phosphate method. COS-
1 cells were transiently transfected in 80-cm2 culture
flasks with 9.4 mg expression plasmid, by use of the
DEAE-dextran method (Gerster et al. 1987). Cells were
shocked with 80 mM chloroquine for 2 h. Transfected
CHO and COS-1 cells were washed after 24 h and were
cultured for another 24 h in either the presence or ab-
sence of 10 nM R1881.
Preparation of Cytosolic Fractions and Nuclear Extracts
GSF were grown until confluence in 175-cm2 culture
flasks, incubated for 24 h in culture medium (Ris-Stal-
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pers et al. 1990) containing 10% hormone-depleted
FCS, and were cultured for another 24 h with medium
either with or without 10 nM R1881. Next, cells were
washed twice in PBS, were collected in 1 ml lysis buffer
A (40 mM Tris, 1 mM EDTA, 10% [v/v] glycerol, 10
mM DTT, 10 mM Na2MoO4, 0.5 mM bacitracin, 0.5
leupeptin, and 0.6 mM phenylmethylsulfonylfluoride
[PMSF]), and were homogenized by freeze-thawing four
times, followed by 10 min centrifugation at 800 g in a
Biofuge (Heraeus) at 47C. The supernatant was centri-
fuged for 10 min at 400,000 g at 47C (TLA120.2 rotor;
Beckman). The cytosol fraction (supernatant) was stored
at 2807C until used. The pellet remaining after the first
800-g centrifugation step was resuspended in buffer B
(buffer A with 0.2% Triton X-100) and incubated for
5 min at 47C, followed by 10 min centrifugation at 800
g in a Biofuge 13. The resulting pellet (nuclear fraction)
was washed with buffer C (buffer A without leupeptin)
and was resuspended in equal volumes of 1 M NaCl
and 0.5 M NaCl and incubated for 1 h at 07C. Nuclear
extract (supernatant) was obtained by centrifugation for
10 min at 400,000 g (TLA120.2 rotor) at 47C. The total
nuclear extract and 250 ml cytosol fraction were taken
separately for immunoprecipitation.
Gel-Retardation Assay
After transfection with pSG5AR0, pSG5AR33, or
pSG5AR129, COS-1 cells were collected in 5 ml PBS.
The pellet was resuspended in extraction buffer (10 mM
NaH2PO4, pH 7.4, 0.4 M KCl, 1 mM EDTA, 10% [v/
v] glycerol, 0.5 mM bacitracin, 0.5 mM leupeptin, 0.6
mM PMSF, and 10 mM DTT) and was frozen and
thawed four times, followed by 10 min centrifugation
at 400,000 g (TLA120.2 rotor) at 47C. The double-
stranded DNA probe containing the ARE from the ty-
rosine aminotransferase (TAT) promoter (5′-
TGACTGTACAGGATGTTCTAGCTACT-3′) (half sites
are in italics) was obtained from Promega. The ARE
probe was end-labeled by use of T4 polynucleotide ki-
nase and g-32P-ATP (specific activity 3,000 Ci/mmol;
Amersham). The double-stranded probe was purified
from a 4% acrylamide gel, in 0.5 # TBE (1 # TBE 5
50 mM Tris base, 50 mM boric acid, and 1 mM EDTA,
pH 8.6). Cellular extracts were incubated in binding
buffer (10 mM HEPES, pH 7.9, 60 mM KCl, 1 mM
DTT, 1 mM EDTA, and 4% Ficoll) containing 1 mg poly-
dIdC, in the absence or presence of AR antibody (Ab)
Sp197 (the epitope is amino acid residues 1–20 from the
AR) (Kuiper et al. 1993). After 10 min incubation on
ice, 2 ml purified DNA probe (50,000 cpm/ml) was added,
and incubation was continued for 20 min at room tem-
perature. The 20-ml sample was separated on a 4% poly-
acrylamide gel in 0.5 # TBE. Gels were fixed for 10
min in 10% acetic acid and 10% methanol and subse-
quently were dried and exposed.
Allele-Specific Oligonucleotide Hybridization
RT-PCR and nested-PCR reactions were performed as
described above (see the Construction of Expression Vec-
tors subsection above). The resulting PCR product was
amplified once more in a PCR reaction of 30 cycles, by
use of exon 1 sense primer 470A and exon 4 antisense
primer 14NB. Plasmid (pSVAR0, BHEX-AR33, and
pSVAR129) fragments were amplified once under iden-
tical conditions, by use of the same primers. Dot blots
were prepared in a Schleicher & Schuell apparatus ac-
cording to the manufacturer’s protocol. In the case of
PCR product obtained by plasmid amplification, an
equivalent amount of DNA was spotted. Membranes
were preincubated for 10 min with hybridization mix
(50 mM NaH2PO4, 0.75 M NaCl, 5 mM EDTA [5 #
SSPE], 1% SDS, and 0.05 mg herring sperm DNA/ml).
For each of the splice variants, specific oligonucleotides
were designed: a wild-type probe, an exon 3–deletion
probe, and a 69-bp-insertion probe (table 1) (Pharmacia
Biotech Benelux). The filters were subsequently hybrid-
ized and rinsed as described by Boehmer et al. (1997),
but at a temperature of 357C instead of 377C. The mem-
branes probed with wild-type probe or exon 3–deletion
probe were washed for an additional 10 or 15 min,
respectively, in 0.1 # SSC and 0.1% SDS at 387C, before
exposure. After autoradiography, the membranes were
stripped and the procedure was repeated with probe
2AA (table 1) as a control.
Results
Screening for Mutations
PCR-SSCP analysis was performed under two con-
ditions to screen for mutations in the AR gene of an
index subject with partial AIS. In the coding part and
the exon-flanking intronic sequences, no mutation was
found. To study segregation of a presumed AR defect,
the length of the AR-gene CAG repeat was determined
in DNA from several family members. Results are pre-
sented in figure 1. The mother (II-2) of the two 46,XY
sisters (III-1 and III-2) had two different alleles, one with
a (CAG)24CAA unit coding for 25 glutamine residues
and one with a (CAG)25CAA unit coding for 26 gluta-
mine residues. The three affected 46,XY individuals (II-
4, III-1, and III-2) had the (CAG)24CAA allele. Therefore,
X-linked inheritance could not be excluded (fig. 1). The
marker was informative, since two brothers (II-1 and II-
3) of the 46,XX carrier had the (CAG)25CAA allele.
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Figure 2 Western blot analysis of wild-type and mutant AR
proteins. A, Western blot, showing receptor isotypes of wild-type AR
and mutant AR. AR protein was prepared from GSF that had been
cultured in the absence (2) or presence (1) of 10 nM R1881. After
immunoprecipitation with monoclonal anti-AR Ab F39.4.1, receptor
protein was separated on a 7% SDS-PAGE gel. After immunoblotting,
the blot was incubated with Sp061, a polyclonal anti-AR Ab. The blot
was washed and then incubated with an alkaline phosphatase–coupled
goat anti-rabbit Ab, to visualize the AR. Lanes 1 and 2, Wild-type
AR. Lanes 3 and 4, Mutant AR. B, Subcellular localization of wild-
type AR and mutant receptor in GSF of patient III-2, after culturing
of GSF in the absence or presence of R1881. GSF were cultured for
24 h either in the absence (2) or presence (1) of 10 nM R1881.
Nuclear and cytosol fractions were prepared, and the AR was im-
munoprecipitated with monoclonal Ab F39.4.1 from both the total
nuclear extract and one-fourth of the cytosol fraction. Western blotting
and immunostaining were performed as described above for panel A.
AR was visualized with a peroxidase-coupled goat anti-rabbit Ab.
Lanes 1 and 2, Cytosol fraction from wild-type GSF. Lanes 3 and 4,
Nuclear extract from wild-type GSF. Lanes 5 and 6, Cytosol fraction
from GSF of patient III-2. Lanes 7 and 8, Nuclear extract from GSF
of patient III-2.
Receptor Characteristics
AR protein isolated from GSF from the index patient
(III-2) appeared as a normal 110–112-kD doublet after
SDS-PAGE and immunoblotting. Hormone-binding par-
ameters were determined in a whole cell–binding assay
of GSF. The receptor displayed an equilibrium dissoci-
ation constant (Kd of 0.08 nM and a maximal number
of binding sites (Bmax) of 64 fmol/mg protein, both within
the normal range (Kd 0.03–0.13 nM; Bmax 39–169 fmol/
mg protein). The AR of patient III-1 displayed a Kd of
0.07 nM and a Bmax of 63 fmol/mg protein. Therefore,
the 46,XY individuals (III-1 and III-2) in this AIS family
were classified as having receptor-positive AIS.
Hormone-Dependent Receptor Phosphorylation
The AR is phosphorylated, and many potential phos-
phorylation sites are located in the part encoded by exon
1. In preparations from cells cultured in the absence of
hormone, usually two receptor isotypes are present,
which are visible as a 110–112-kD doublet on an SDS-
PAGE immunoblot (Kuiper et al. 1991). AR protein was
isolated from control GSF and from GSF of the index
patient (III-2). In both GSF preparations, cultured in the
absence of androgens, both the 110- and the 112-kD
AR isotypes were present (fig. 2A, lanes 1 and 2). The
AR from patient III-2 contains a relatively long gluta-
mine stretch (25 glutamines, compared with 19 in the
control AR), resulting in a slower migration pattern. On
hormone binding, the AR undergoes additional phos-
phorylation, reflected by a 114-kD isoform. The ap-
pearance of this isoform is dependent on DNA binding
and/or transcription activation (Jenster et al. 1994). This
hormone-induced phosphorylation was used as a marker
for proper receptor functioning. Control cells cultured
in the presence of hormone displayed the expected,
slower-migrating, third isoform (114 kD) (fig. 2A, lane
2). However, the 114-kD isoform was hardly detectable
in preparations derived from patient III-2 (fig. 2A,
lane 4).
Subcellular Localization Studies in GSF of the Index
Subject
Because the appearance of the 114-kD isoform de-
pends on DNA binding (Jenster et al. 1994), we inves-
tigated whether AR was detectable in the tightly nuclear-
bound AR fraction in GSF from the patient. Control
GSF and GSF from the index patient were cultured in
either the absence or presence of 10 nM R1881, and
cytosol and nuclear fractions were prepared. When cells
were cultured in the absence of hormone, AR was found
in the cytosol fraction (fig. 2B, lanes 1 and 5) but not
in the nuclear fraction (fig. 2B, lanes 3 and 7). After
culture in the presence of hormone, although AR was
still detectable in the cytosol fraction (fig. 2B, lanes 2
and 6), wild-type AR was clearly present in the nuclear
extract (fig. 2B, lane 4), whereas AR protein was not
observed in the nuclear extract of the patient’s GSF (fig.
2B, lane 8). This suggests a defect in DNA binding of
the AR in the index patient (III-2).
Mutation Detection and the Mutation’s Effect on the
Splicing Process
Although PCR-SSCP analysis was not informative
about an AR-gene mutation in patient III-2, the AR gene
was studied in more detail. Sequencing of the flanking
intronic regions of exons 2 and 3 of the AR gene of
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Figure 3 Characterization of point mutation. A, Position of
point mutation found in intron 2. Represented are exons 2 and 3 and
significant sequences flanking intron 2, of both wild-type and mutant
AR pre-mRNAs. The positions of the splice-donor site, the branch site,
and the splice-acceptor site are indicated. The mutation is located at
position 211 in intron 2 in the conserved pyrimidine-rich region 5′
upstream of the splice-acceptor site of intron 2. B, Illustration of wild-
type and aberrant splicing process resulting from intron 2 mutation.
Blackened bars represent exons 2–4; and the diagonally hatched bar
represents 69 additional nucleotides. Mutant transcript I and mutant
transcript II were found by RT-PCR studies on GSF mRNA from the
index subject.
patient III-2 demonstrated a mutation (TrA) 11 bp up-
stream of exon 3 (fig. 3A). The same mutation was found
in the AR gene of patients II-4 and III-1. Because the
mutation is located in the region where the forward pri-
mer (fig. 3A) anneals, the mutation remained undetected
in PCR-SSCP analysis. In RT-PCR experiments, two dif-
ferent receptor variants were found. Predominantly, a
transcript containing 69 additional nucleotides between
the sequences of exons 2 and 3 (mutant transcript I) and
a smaller amount of a transcript from which exon 3 was
deleted (mutant transcript II) (fig. 3B) were detected.
Translation of transcript I will result in an AR with a
23-amino-acid insertion between the two zinc clusters,
and transcript II encodes a protein that lacks the second
zinc cluster. Wild-type transcript was not detected by
RT-PCR. SDS-PAGE and immunoblot analysis revealed
only a protein with an increased molecular mass in GSF
from patient III-2 (fig. 2A, lanes 3 and 4). The 23 ad-
ditional amino acid residues, as well as the relatively
long glutamine stretch, contributed to the slower mi-
gration pattern seen with SDS-PAGE analysis, as com-
pared with the control AR.
To prove that the mutation at position 211 is not a
common polymorphism, 102 normal chromosomes
from unrelated individuals were screened for the pres-
ence of this mutation in intron 2 of the AR gene. The
mutation was not detected in these control individuals.
In addition, a larger part of intron 2 of the AR gene of
the index patient was sequenced to exclude the presence
of an additional mutation that could have induced the
preferential use of the cryptic splice site. No other al-
terations were found in intron 2, up to position 2137.
Immunoblot Analysis of the AR Protein
The expression plasmids pSG5AR0, pSG5AR129, and
pSG5AR33, encoding the wild-type AR, AR TI, and AR
TII, respectively, were transiently expressed in COS-1
cells. In the cells transfected with pSG5AR0, the 114-
kD isoform was detected after culture in the presence of
hormone. However, cells transiently transfected with ei-
ther one of the receptor mutants almost lacked this third
isoform (fig. 4A, lanes 4 and 6).
Gel-Retardation Assay
In order to establish whether DNA binding by the
mutant AR was affected, in vitro binding to a consensus
ARE was studied. In the presence of polyclonal Ab
Sp197, which stabilizes the protein-DNA complex (Kui-
per et al. 1993), the wild-type receptor was able to bind
to a consensus ARE, resulting in a shifted probe (fig.
4B, lane 5). No shifted probe was detected for the mu-
tant AR TI and AR TII (fig. 4B, lanes 7 and 9) or in the
control lane (fig. 4B, lane 3). The amount of receptor
protein was checked by western blotting and immuno-
staining. Comparable amounts of AR protein were
incubated.
Transcription-Activation Assay
The wild-type AR showed transcription activation on
the MMTV promoter in CHO cells (fig. 4C). However,
AR TI and AR TII were unable to activate transcription
on an MMTV-Luc promoter (fig. 4C). SDS-PAGE fol-
lowed by immunoblotting showed that AR-protein ex-
pression was identical for the three different receptor
molecules (results not shown).
Allele-Specific Oligonucleotide Hybridization
To investigate whether a wild-type transcript was pres-
ent in GSF of the two affected siblings in the partial-AIS
family, an allele-specific oligonucleotide–hybridization
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Figure 4 Functional analysis of wild-type and mutant AR. A, Hormone-induced upshift of AR proteins. AR protein variants were expressed
in COS-1 cells after transfection with pSG5AR0, pSG5AR33, or pSG5AR129. The cells were cultured for 24 h in the absence (2) or presence
(1) of 10 nM R1881. After immunoprecipitation using monoclonal Ab F39.4.1, SDS-PAGE was performed, followed by immunoblotting. AR
was detected by immunostaining using polyclonal Ab Sp061 and an alkaline phosphatase–coupled anti-rabbit Ab. Lanes 1 and 2, Wild-type
AR. Lanes 3 and 4, AR deletion mutant. Lanes 5 and 6, AR insertion mutant. B, Gel-retardation assay. Cell extracts prepared from COS-1
cells were incubated for 10 min on ice, in binding buffer with poly-dIdC, in either the presence (1) or absence (2) of polyclonal anti-AR Ab
Sp197. Labeled ARE probe (50,000 cpm) was added, and the samples were incubated for 20 min at room temperature. Complexes were
analyzed by PAGE, as described in Subjects and Methods. The position of the shifted complexes is indicated by an arrow, and “FP” indicates
the position of the free probe. Lane 1, Free probe. Lanes 2 and 3, COS-1 extract. Lanes 4 and 5, Wild-type AR (WT). Lanes 6 and 7, Mutant
AR encoded by transcript I (TI). Lanes 8 and 9, Mutant AR encoded by transcript II (TII). C, Transcriptional activity. CHO cells were cotransfected
with MMTV-Luc reporter plasmid and with either wild-type or mutant AR expression plasmid. Twenty-four hours before a luciferase assay
was performed, cells were incubated with increasing concentrations of R1881. Each data point was tested in triplicate. M 5 mean-fold induction
5 SEM calculated for wild-type AR, for three different experiments; n 5 mean-fold induction 5 SEM calculated for the AR mutant with
insertion of 23 amino acids; and m 5 mean-fold induction 5 SEM calculated for the AR mutant with the exon 3 deletion.
assay was developed. First-strand cDNA was synthesized
from total mRNA, was derived from GSF, and was am-
plified in three consecutive PCR reactions. mRNA was
isolated from wild-type GSF, from GSF from patients III-
1 and III-2, and as a control from GSF derived from a
patient with partial AIS who has been described previ-
ously by Ris-Stalpers et al. (1994). The mutation found
in this latter patient causes differential splicing, resulting
in 10% wild-type mRNA and 90% mRNA of a splice
variant with a deletion of exon 3. The PCR products
were spotted on membranes and subsequently hybrid-
ized with oligonucleotides specific for the splice variants
and the wild-type AR (table 1). Hybridization with the
wild-type probe revealed wild-type mRNA in GSF from
a normal control male, in GSF from the partial-AIS pa-
tient (positive control), and in GSF from one of the
46,XY patients (III-1) (fig. 5, WT-1b, WT-1c, and WT-
1d, respectively). In GSF from patient III-2, wild-type
transcript was either not present or below the detection
limit of the assay (fig. 5, WT-1e). TI was present only
in GSF from patients III-1 and III-2 and not in wild-type
GSF (fig. 5, TI-3d and TI-3e, respectively). TII was de-
tected in GSF of the positive control and patient III-1
(fig. 5, TII-5c and TII-5d, respectively). The signal at
position e in figure 5 (patient III-2), which was com-
parable to the a-specific signal at position b in figure 5,
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Figure 5 Allele-specific oligonucleotide hybridization. DNAs
were amplified by use of exon 1 sense primer 470A and exon 4 an-
tisense primer 14 NB, in two consecutive PCR reactions. The expres-
sion plasmids used as controls (pSVAR0, BHEX-AR33, and
pSVAR129) were amplified in one PCR reaction. The resulting PCR
products were spotted on three separate membranes, which were sub-
sequently hybridized with allele-specific oligonucleotides, as described
in Subjects and Methods: WT 5 wild-type probe; TI 5 69-bp-insertion
mutant; and TII 5 exon 3 deletion mutant. For lanes 1 (WT), 3 (TI),
and 5 (TII), a 5 blank; b 5 amplified cDNA of normal control; c 5
amplified cDNA of a patient with Reifenstein syndrome; d 5 amplified
cDNA of patient III-1; and e 5 amplified cDNA of patient III-2. For
lanes 2 (WT), 4 (TI), and 6 (TII), a 5 denaturation buffer; b 5 am-
plified wild-type expression plasmid; c 5 amplified expression plasmid
(BHEX-AR33); d 5 amplified expression plasmid (pSVAR129); and e
5 mixture of amplified expression plasmids pSVAR0, BHEX-AR33,
and pSVAR129 (ratio 1:1:8).
resulted from cross-hybridization of the probe with wild-
type DNA and was considered as background. DNA
amplified from expression plasmids, which was used as
a positive control, is visible in rows 2, 4, and 6 of figure
5. Comparable amounts of DNA were spotted, as was
assessed by hybridization with an exon 2 probe (results
not shown).
Discussion
It is well established that AIS is caused by mutations
in the AR gene. However, reports have appeared about
patients with an AIS phenotype in which no mutation
was detected by use of PCR-SSCP analysis (Bru¨ggen-
wirth et al. 1996; Weidemann et al. 1996) and DNA
sequencing (Morel et al. 1994), in spite of clear phe-
notypic, endocrinological, and biochemical evidence for
AIS. Mutations might be missed because PCR-SSCP is
not 100% sensitive. Often, only the exonic sequences
and their flanking intronic regions are screened, leaving
mutations in intronic and promoter regions undetected.
For the AR, if cells from patients are available, RT-PCR
studies and western immunoblotting can be very in-
formative, in particular when mutations are present in
intronic regions (Ris-Stalpers et al. 1990, 1994).
In the present report, a family presenting with partial
AIS has been described. No mutation was detected in
the AR gene of the index patient after PCR-SSCP anal-
ysis or sequencing of the exons. However, biochemical
studies revealed that the AR of the affected family mem-
bers was unable to bind to DNA. In the absence of
hormone, wild-type receptor derived from transiently
transfected COS-1 cells migrates as a 110–112-kD dou-
blet (Kuiper et al. 1991). AR preparations derived from
cells cultured in the presence of hormone contain, in
addition to the 110–112-kD doublet, a slower-migrat-
ing, 114-kD isoform, representing hormone-dependent
phosphorylation (Jenster et al. 1994). It has been shown
that the appearance of the 114-kD isoform is correlated
with DNA binding and/or transcription activation (Jen-
ster et al. 1994). In the present report, hormone-de-
pendent phosphorylation of the AR protein has been
used as an indicator of receptor dysfunctioning. Since
the 114-kD isoform was hardly detectable in GSF de-
rived from the index subject (III-2) and her sister (III-
1), cellular distribution of the AR from the index subject
was studied. AR was undetectable in the tightly nuclear-
bound fraction of hormone-exposed GSF from the index
subject, which points to disturbed AR-DNA binding
and, consequently, to a defect in transcription activation.
Sequencing analysis revealed a mutation at position 211
in intron 2, in the AR gene of both siblings, their 46,XY
aunt, and the index patient’s mother (carrier of the mu-
tation). Since this mutation was not found in 102 chro-
mosomes derived from unrelated controls, we have con-
cluded that it is not a common polymorphism.
The effect of the mutation on the splicing process has
been studied. Splicing of pre-mRNA begins with cleav-
age at the 5′ splice-donor site, which is attacked by the
2-OH group of the branch-site adenosine. The 3′ splice
site is attacked by the newly formed 3′-OH of the up-
stream exon, the intron is released in the form of a lariat,
and the exons are joined (Sharp 1985). Around the
splice-acceptor site a consensus sequence (T/C, T/C, T,
T, T/C, T/C, T/C, T/C, T/C, T/C, N, C, A, G, G) im-
portant for proper splicing is present (Shapiro and Sen-
apathy 1987). The present AR mutation was located in
this pyrimidine-rich consensus sequence preceding the
splice-acceptor site. Aberrant splicing took place, re-
sulting in different transcripts encoding defective ARs,
which might explain the observed phenotype. The cryp-
tic splice site that was used is located at position 271/
270 in intron 2, thus resulting in an mRNA variant
containing an insertion of 69 nucleotides. We determined
that sequences in and around this cryptic splice site did
not contain any mutation, thereby not enhancing pref-
erable usage of this site.
According to Nakai and Sakamoto (1994), almost all
major cryptic splice sites that are activated by mutations
are located !100 nucleotides from the original splice site.
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On the basis of comparison with a consensus sequence,
the cryptic splice site located at position 271/270 in
the AR appears to be closer to the consensus sequence
than does the wild-type splice-acceptor site (the cryptic
splice site is T, C, T, T, T, T, C, T, G, T, T, C, T, A, G,
A; the wild-type intron 2 splice site is T, A, T, T, T, G,
T, T, C, T, C, C, C, A, G, C). However, RT-PCR studies
performed on wild-type mRNA demonstrated that this
cryptic splice site is normally not used. Watakabe et al.
(1993) proposed that suboptimal 3′ splice-site sequences
require stimulation by downstream sequences. Thus,
exon 3 sequences of the AR may play a role in splice-
acceptor-site selection. The newly created splice-acceptor
site at position 211/210 was not used, probably be-
cause, compared with the novel cryptic site at position
271/270, the sequence was less favorable for splicing.
A small amount of a transcript from which exon 3 was
deleted was detected. Wild-type transcript was not ob-
served, although this could be expected on the basis of
the partial-AIS phenotype of the affected individuals. We
concluded that the wild-type splice-acceptor site has be-
come weaker because of the base-pair substitution at
position 211. Alternatively, closely spaced splice sites
can inactivate each other because of sterical hindrance
of bound splicing factors (Black 1991). Nelson and
Green (1988) showed with in vitro splicing experiments
that, in a b-globin intron, insertion of a new splice-donor
site close to the wild-type splice-donor site prevented
splicing at both sites. Therefore, aberrant splicing in our
patients could also be the result of interference by two
closely spaced splice-acceptor sequences.
Quigley et al. (1992) have described the so-called null
phenotype of AIS. A deletion of the X chromosome span-
ning the complete AR gene caused complete AIS. The
patient showed inguinal or abdominal testes, no Wolf-
fian-duct development, and absence of masculinization
of the external genitalia. Sparse pubic and axillary hair
were detected. Also, a complete external female phe-
notype and absence of secondary hair were seen in a
46,XY individual with a complete deletion of the AR
gene, as reported by Hiort et al. (1996). All AIS subjects
in the family reported in the present paper showed rem-
nants of vasa deferentia and epididymides. The aunt (II-
4), clinically investigated postpubertally, has pubic and
axillary hair. These phenotypic characteristics suggest
that some residual AR activity is present. Therefore,
DNA binding and transcription-activation capacities of
the splice variants were investigated. The AR expressed
in GSF from the index subject has 23 additional amino
acids between the first zinc cluster and the second zinc
cluster. Ducouret et al. (1995) cloned a teleost-fish glu-
cocorticoid receptor (GR) with nine additional amino
acid residues between the two zinc clusters. This fish
GR, however, was still capable of activating a reporter
gene, from which it was concluded that the folding of
the GR can compensate for separation of the two zinc
clusters by an extra 9-amino-acid stretch. The AR mu-
tant with the insertion of 23 amino acid residues did not
bind to a consensus ARE (on the basis of a gel-retar-
dation assay). Consequently, there was absence of tran-
scription activation. The splice variant with a deletion
of the second zinc cluster was also unable to bind spe-
cifically to DNA, corresponding to the results reported
by Quigley et al. (1992) and Ris-Stalpers et al. (1994).
On the basis of these results and in view of the phenotype
of the affected family members, we concluded that splic-
ing was not completely aberrant. Indeed, a very small
amount of wild-type transcript was detected in GSF of
patient III-1, by use of the allele-specific oligonucleo-
tide–hybridization method. The transcript with the de-
letion of exon 3 (i.e., AR TII) was detected in GSF of
patient III-1 and not in GSF of patient III-2. However,
this was not reproduced in all experiments, since AR TII
previously had been detected by RT-PCR studies using
RNA from patient III-2.
The intronic mutation discussed in this paper was
missed by PCR-SSCP analysis. There are several other
explanations for the apparent absence of AR mutations
in several cases of AIS. Neutral mutations, for example,
have to be interpreted with caution. Richard and Beck-
mann (1995) found a synonymous-codon mutation
(GGCrGGT) in the cDNA of the calpain (CANP3) gene,
which turned out to be pathogenic, because a splice-
donor site was created. Kallio et al. (1996) suggested
that, in 46,XY subjects without a mutation in the AR
gene and with a typical AIS phenotype, postreceptor
defects might be the cause of the disease. This may in-
volve receptor-specific cofactors or corepressors. Re-
cently, a family with dominant inheritance of thyroid-
hormone resistance was reported, which could not be
linked to defects in the thyroid hormone–receptor a or
b genes (Weiss et al. 1996). It was postulated that an
abnormal cofactor, playing a role in regulation of thy-
roid-hormone action, might be involved. Most cofactors
reported to date are not AR specific, so mutations in
these factors will probably be lethal or give rise to com-
plex phenotypes. One coactivator, ARA70, which binds
specifically to the ligand-bound AR, has been reported
by Yeh and Chang (1996). It is not known whether
mutations in the gene encoding ARA70 correlate with
certain forms of AIS.
In conclusion, the mutation presented in this paper
remained undetected by PCR-SSCP analysis. AR genes
from AIS subjects for whom the clinical diagnosis is well
established and in whom no mutation can be detected
after PCR-SSCP screening and additional sequencing of
the coding parts of the gene should be analyzed for in-
tronic mutations. RT-PCR studies and western immu-
noblotting, using cultured GSF, can provide important
information.
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